Back to news

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire•17/11/2026•16:01 ET
0

Key Highlights

  • ➤21,250 RSUs granted to three individuals as inducement awards
  • ➤RSUs granted November 2, 2026, vesting over three years
  • ➤Awards comply with Nasdaq Listing Rule 5635(c)(4)
  • ➤Delcath's HEPZATO KIT is FDA-approved for eligible metastatic uveal melanoma patients

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose grant date was in either September 2026 or October 2026.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in